Acadia Pharmaceuticals Inc (NASDAQ: ACAD)’s stock price has dropped by -1.28 in relation to previous closing price of 14.81. Nevertheless, the company has seen a loss of -0.81% in its stock price over the last five trading days. zacks.com reported 2024-10-30 that Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is It Worth Investing in Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Right Now?
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has a higher price-to-earnings ratio of 81.90x compared to its average ratio, The 36-month beta value for ACAD is at 0.37. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ACAD is 164.61M, and currently, shorts hold a 4.97% of that float. The average trading volume for ACAD on November 05, 2024 was 1.48M shares.
ACAD’s Market Performance
The stock of Acadia Pharmaceuticals Inc (ACAD) has seen a -0.81% decrease in the past week, with a -3.18% drop in the past month, and a -22.44% fall in the past quarter. The volatility ratio for the week is 2.51%, and the volatility levels for the past 30 days are at 2.63% for ACAD. The simple moving average for the past 20 days is -0.74% for ACAD’s stock, with a -18.44% simple moving average for the past 200 days.
Analysts’ Opinion of ACAD
Morgan Stanley, on the other hand, stated in their research note that they expect to see ACAD reach a price target of $20, previously predicting the price at $28. The rating they have provided for ACAD stocks is “Equal-Weight” according to the report published on August 07th, 2024.
BMO Capital Markets gave a rating of “Outperform” to ACAD, setting the target price at $31 in the report published on June 27th of the current year.
ACAD Trading at -5.15% from the 50-Day Moving Average
After a stumble in the market that brought ACAD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.14% of loss for the given period.
Volatility was left at 2.63%, however, over the last 30 days, the volatility rate increased by 2.51%, as shares sank -0.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.28% lower at present.
During the last 5 trading sessions, ACAD fell by -0.81%, which changed the moving average for the period of 200-days by -46.43% in comparison to the 20-day moving average, which settled at $14.73. In addition, Acadia Pharmaceuticals Inc saw -53.31% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACAD starting from Schneyer Mark C., who sale 9,733 shares at the price of $15.28 back on Aug 19 ’24. After this action, Schneyer Mark C. now owns 43,735 shares of Acadia Pharmaceuticals Inc, valued at $148,720 using the latest closing price.
Teehan Brendan, the EVP, COO, HEAD OF COMMERCIAL of Acadia Pharmaceuticals Inc, sale 9,534 shares at $15.28 during a trade that took place back on Aug 19 ’24, which means that Teehan Brendan is holding 52,177 shares at $145,680 based on the most recent closing price.
Stock Fundamentals for ACAD
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.92 for the gross margin
The net margin for Acadia Pharmaceuticals Inc stands at 0.03. The total capital return value is set at 0.04. Equity return is now at value 6.70, with 3.93 for asset returns.
Based on Acadia Pharmaceuticals Inc (ACAD), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 1.4.
Currently, EBITDA for the company is -67.83 million with net debt to EBITDA at -3.67. When we switch over and look at the enterprise to sales, we see a ratio of 2.59. The receivables turnover for the company is 8.07for trailing twelve months and the total asset turnover is 0.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.16.
Conclusion
In conclusion, Acadia Pharmaceuticals Inc (ACAD) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
